Health Technology Astellas Pharma, Inc. Business Summary
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.
Financial Highlights
Mar 2022
JPY USD Revenue 1,296.16B 11,534.50M Gross Profit 1,014.87B 9,031.29M Operating income 220,021M 1,957.95M Income before tax 156,397M 1,391.77M Net income 124,086M 1,104.23M EBITDA 299,705M 2,667.06M Diluted EPS 67.05 0.59 Dividends Per Share 50 0.44 Total Assets 2,332.39B 19,216.43M Total liabilities 872,086M 7,185.05M Total equity 1,460.30B 12,031.37M Operating cash flow 258,160M 2,297.35M Currency in JPY Currency in USD
Historical Data Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Revenue
1,300.31B
1,306.34B
1,300.84B
1,249.52B
1,296.16B
Gross Profit
970,228M
979,086M
1,002.94B
979,702M
1,014.87B
Operating income
271,241M
280,141M
279,419M
250,897M
220,021M
Income before tax
218,113M
248,967M
247,010M
144,846M
156,397M
Net income
164,679M
222,265M
195,411M
120,589M
124,086M
EBITDA
336,104M
343,599M
345,815M
323,549M
299,705M
Diluted EPS
81.02
114.94
104.07
64.89
67.05
Dividends Per Share
36
38
40
42
50
Total Assets
1,858.20B
1,897.64B
2,315.16B
2,273.62B
2,332.39B
Total liabilities
589,916M
639,252M
1,026.00B
887,514M
872,086M
Total equity
1,268.28B
1,258.39B
1,289.16B
1,386.11B
1,460.30B
Operating cash flow
314,463M
261,428M
224,060M
307,880M
258,160M
Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Revenue
11,732.27M
11,780.07M
11,964.43M
11,781.61M
11,534.50M
Gross Profit
8,754.00M
8,828.97M
9,224.49M
9,237.46M
9,031.29M
Operating income
2,447.30M
2,526.19M
2,569.94M
2,365.67M
1,957.95M
Income before tax
1,967.95M
2,245.07M
2,271.86M
1,365.73M
1,391.77M
Net income
1,485.83M
2,004.28M
1,797.28M
1,137.01M
1,104.23M
EBITDA
3,032.54M
3,098.42M
3,180.61M
3,050.69M
2,667.06M
Diluted EPS
0.73
1.03
0.95
0.61
0.59
Dividends Per Share
0.32
0.34
0.36
0.39
0.44
Total Assets
17,472.54M
17,144.58M
21,445.68M
20,575.81M
19,216.43M
Total liabilities
5,546.92M
5,775.41M
9,503.95M
8,031.80M
7,185.05M
Total equity
11,925.61M
11,369.16M
11,941.71M
12,544.02M
12,031.37M
Operating cash flow
2,837.28M
2,357.44M
2,060.78M
2,902.95M
2,297.35M
Valuation Measures
Mar 2022
PER 28.48 ROA 5.38% ROE 8.71% Operating margin 16.97% Profit margin 9.57%
Key executives
Chairman, President & Chief Executive Officer:
Kenji Yasukawa
Chief Financial Officer:
Minoru Kikuoka
Chief Scientific Officer:
Yoshitsugu Shitaka
Head-Business Administration & Compliance:
Fumiaki Sakurai
VP, Head-Oncology Therapeutic Area in Mktg Strat:
Peter Sandor Shareholders
Nomura Asset Management Co., Ltd. (6.2%)
Wellington Management Co. LLP (4.2%)
Daiwa Asset Management Co. Ltd. (2.8%)
Nikko Asset Management Co., Ltd. (2.8%)
Nippon Life Insurance Co. (2.8%)
The Vanguard Group, Inc. (2.7%)
BlackRock Fund Advisors (1.8%)
Mitsubishi UFJ Kokusai Asset Management Co., Ltd. (1.5%)
Norges Bank Investment Management (1.5%)
T. Rowe Price Associates, Inc. (Investment Management) (0.9%)
Contact Details Website: http://www.astellas.com Address:
2-5-1 Nihonbashi-Honcho,
Chuo-Ku,
Tokyo,
103-8411,
Japan
Phone:
+81.3.3244.3000
Related Companies
Astellas Pharma, Inc. /5 Legacy Products/
Astellas Pharma, Inc. /Milrila Injection Product/
OSI Pharmaceuticals, LLC
Representative Office of Astellas Pharma Singapore
Astellas Pharma Malaysia Sdn. Bhd.
Astellas Green Supply, Inc.
Xyphos Biosciences, Inc.
Iota Biosciences, Inc.
Astellas Pharma, Inc. /Agensys Research Facilities/
Astellas Pharma, Inc. /16 Long Listed Products/
Astellas Farma Colombia
Astellas Pharma Director Incentive Plan
Quethera Ltd.
PT Astellas Pharma Indonesia
Astellas Pharma ZAO
Astellas Pharma Hong Kong Co., Ltd.
Astellas Pharma India Pvt Ltd.
Astellas Pharma (Thailand) Co., Ltd.
Astellas Pharma Australia Pty Ltd.
Astellas Pharma Singapore Pte Ltd.
Astellas Pharma Tech Co., Ltd.
Astellas Gene Therapies, Inc.
Mitobridge, Inc.
Astellas Pharma China, Inc.
Perseid Therapeutics LLC
GPDC Partnership
Astellas Pharma Philippines, Inc.
Astellas Pharma Co. Ltd.
Astellas Pharma Canada, Inc.
Fujisawa Taiwan Co. Ltd.
Competitors
AstraZeneca PLC
JW Holdings Corporation
Lantern Pharma, Inc.
AbClon, Inc.
Eledon Pharmaceuticals, Inc.
DexTech Medical AB
Poseida Therapeutics, Inc.
OSE Immunotherapeutics SA
ADC Therapeutics Ltd
MedPacto, Inc.
Bicycle Therapeutics Plc Sponsored ADR
Golden Biotechnology Corp.
Agenus Inc.
DongKoo Bio & Pharm Co. Ltd.
LegoChem Biosciences, Inc.
Akebia Therapeutics, Inc.
Cullinan Oncology, Inc.
Editas Medicine, Inc.
ERYTech Pharma SA
Keros Therapeutics, Inc.
Kura Oncology, Inc.
Foresee Pharmaceuticals Co., Ltd.
GlycoMimetics, Inc.
LogicBio Therapeutics, Inc.
Ambrx Biopharma, Inc. Sponsored ADR
Aptevo Therapeutics Inc
Cyclerion Therapeutics,Inc.
ImmunoGen, Inc.
Silence Therapeutics PLC Sponsored ADR
Cellectis SA
Copyright © 2022 FactSet Research Systems Inc. All rights reserved.
Last Updated on 4 Oct, 2022
Take your reading anywhere with offline reading functions Never miss a story with breaking news alerts Customize your reading experience
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapter Find out more
By continuing to browse this website, you accept cookies which are used for several reasons such as personalizing content/ads and analyzing how this website is used. Please review our
Cookie Policy
to learn how you can update your cookie settings.
Accept & Continue
Close
